thiotepa has been researched along with Invasiveness, Neoplasm in 13 studies
Thiotepa: A very toxic alkylating antineoplastic agent also used as an insect sterilant. It causes skin, gastrointestinal, CNS, and bone marrow damage. According to the Fourth Annual Report on Carcinogens (NTP 85-002, 1985), thiotepa may reasonably be anticipated to be a carcinogen (Merck Index, 11th ed).
| Excerpt | Relevance | Reference |
|---|---|---|
| "This report presents the second interim analysis of data from a randomized prospective trial that compares the prophylactic effect of 15 intravesical instillations of 50 mg Doxorubicin (ADM), 50 mg of Thiotepa (TTPA), or 150 mg of Bacillus Calmette-Guérin (BCG) against recurrence and progression of superficial transitional cell bladder cancer." | 9.06 | Intravesical therapy comparing BCG, adriamycin, and thiotepa in 200 patients with superficial bladder cancer: a randomized prospective study. ( Cárcamo, P; Fiter, L; García Matres, MJ; Jimenez León, J; Martinez-Pineiro, JA; Martinez-Pineiro, L; Mosteiro, JA; Navarro, J, 1989) |
| "Mitomycin-C (MMC) and thiotepa are intravesical agents effective in reducing the recurrence of low-grade noninvasive bladder cancer when instilled perioperatively." | 7.91 | Single-dose perioperative mitomycin-C versus thiotepa for low-grade noninvasive bladder cancer. ( Blodgett, G; Castle, EP; Chang, YH; Etzioni, DA; Faraj, K; Habermann, EB; Humphreys, MR; Rose, KM; Tyson Ii, MD, 2019) |
| " These patients with progressive bladder carcinoma appeared to be unaffected by intravesical thiotepa in the dosage used." | 5.27 | Intravesical thiotepa prophylaxis of superficial bladder cancer. A follow-up study. ( Fosså, SD; Miller, A; Stenwig, AE, 1983) |
| "This report presents the second interim analysis of data from a randomized prospective trial that compares the prophylactic effect of 15 intravesical instillations of 50 mg Doxorubicin (ADM), 50 mg of Thiotepa (TTPA), or 150 mg of Bacillus Calmette-Guérin (BCG) against recurrence and progression of superficial transitional cell bladder cancer." | 5.06 | Intravesical therapy comparing BCG, adriamycin, and thiotepa in 200 patients with superficial bladder cancer: a randomized prospective study. ( Cárcamo, P; Fiter, L; García Matres, MJ; Jimenez León, J; Martinez-Pineiro, JA; Martinez-Pineiro, L; Mosteiro, JA; Navarro, J, 1989) |
| "Mitomycin-C (MMC) and thiotepa are intravesical agents effective in reducing the recurrence of low-grade noninvasive bladder cancer when instilled perioperatively." | 3.91 | Single-dose perioperative mitomycin-C versus thiotepa for low-grade noninvasive bladder cancer. ( Blodgett, G; Castle, EP; Chang, YH; Etzioni, DA; Faraj, K; Habermann, EB; Humphreys, MR; Rose, KM; Tyson Ii, MD, 2019) |
| "One hundred fifty-five patients with urinary bladder cancer who were not suitable for radical surgery were treated with full-course radiotherapy, 6600 cGy in 9 weeks, split-course." | 1.28 | Recurrence and treatment of urinary bladder cancer after failure in radiotherapy. ( Salminen, E, 1990) |
| " These patients with progressive bladder carcinoma appeared to be unaffected by intravesical thiotepa in the dosage used." | 1.27 | Intravesical thiotepa prophylaxis of superficial bladder cancer. A follow-up study. ( Fosså, SD; Miller, A; Stenwig, AE, 1983) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 10 (76.92) | 18.7374 |
| 1990's | 1 (7.69) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 2 (15.38) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Faraj, K | 1 |
| Chang, YH | 1 |
| Rose, KM | 1 |
| Habermann, EB | 1 |
| Etzioni, DA | 1 |
| Blodgett, G | 1 |
| Castle, EP | 1 |
| Humphreys, MR | 1 |
| Tyson Ii, MD | 1 |
| Miura, Y | 1 |
| Toyooka, N | 1 |
| Iwai, F | 1 |
| Matsui, Y | 1 |
| Hirai, M | 1 |
| Kaneko, H | 1 |
| Watanabe, M | 1 |
| Tsudo, M | 1 |
| Fosså, SD | 1 |
| Miller, A | 1 |
| Stenwig, AE | 1 |
| Green, DF | 1 |
| Robinson, MR | 1 |
| Glashan, R | 1 |
| Newling, D | 1 |
| Dalesio, O | 1 |
| Smith, PH | 2 |
| Barrett, N | 1 |
| Farrow, GM | 2 |
| Utz, DC | 2 |
| Rife, CC | 1 |
| Greene, LF | 1 |
| Salminen, E | 1 |
| Martinez-Pineiro, JA | 1 |
| Jimenez León, J | 1 |
| Martinez-Pineiro, L | 1 |
| Fiter, L | 1 |
| Mosteiro, JA | 1 |
| Navarro, J | 1 |
| García Matres, MJ | 1 |
| Cárcamo, P | 1 |
| Soloway, MS | 2 |
| Stanisic, TH | 1 |
| Donovan, JM | 1 |
| Lebouton, J | 1 |
| Graham, AR | 1 |
| Hardeman, SW | 1 |
| Perry, A | 1 |
| Zincke, H | 1 |
1 review available for thiotepa and Invasiveness, Neoplasm
| Article | Year |
|---|---|
Chemotherapy of bladder cancer: a review.
Topics: Administration, Topical; Antineoplastic Agents; Clinical Trials as Topic; Doxorubicin; Drug Evaluati | 1981 |
2 trials available for thiotepa and Invasiveness, Neoplasm
| Article | Year |
|---|---|
Chemotherapy of bladder cancer: a review.
Topics: Administration, Topical; Antineoplastic Agents; Clinical Trials as Topic; Doxorubicin; Drug Evaluati | 1981 |
Intravesical therapy comparing BCG, adriamycin, and thiotepa in 200 patients with superficial bladder cancer: a randomized prospective study.
Topics: Administration, Intravesical; Adult; Aged; Aged, 80 and over; BCG Vaccine; Carcinoma, Transitional C | 1989 |
11 other studies available for thiotepa and Invasiveness, Neoplasm
| Article | Year |
|---|---|
Single-dose perioperative mitomycin-C versus thiotepa for low-grade noninvasive bladder cancer.
Topics: Administration, Intravesical; Aged; Aged, 80 and over; Antibiotics, Antineoplastic; Antineoplastic A | 2019 |
[Sustained complete remission of intravascular large B-cell lymphoma with recurrent CNS involvement by autologous peripheral blood stem cell transplantation preconditioned with TBC regimen].
Topics: Adult; Antineoplastic Agents, Alkylating; Antineoplastic Combined Chemotherapy Protocols; Brain Neop | 2011 |
Intravesical thiotepa prophylaxis of superficial bladder cancer. A follow-up study.
Topics: Drug Administration Schedule; Female; Follow-Up Studies; Humans; Male; Middle Aged; Neoplasm Invasiv | 1983 |
Does intravesical chemotherapy prevent invasive bladder cancer?
Topics: Administration, Topical; Aged; Antineoplastic Agents; Carcinoma, Transitional Cell; Follow-Up Studie | 1984 |
Cancer of the bladder; a case history.
Topics: Aged; Carcinoma, Transitional Cell; Humans; Male; Middle Aged; Neoplasm Invasiveness; Neoplasm Stagi | 1981 |
Clinical observations on sixty-nine cases of in situ carcinoma of the urinary bladder.
Topics: Adult; Aged; Anaplasia; Carcinoma in Situ; Carcinoma, Transitional Cell; Cystoscopy; Female; Humans; | 1977 |
Recurrence and treatment of urinary bladder cancer after failure in radiotherapy.
Topics: Adult; Aged; Aged, 80 and over; Combined Modality Therapy; Doxorubicin; Female; Humans; Male; Middle | 1990 |
Selecting initial therapy for bladder cancer.
Topics: Administration, Intravesical; BCG Vaccine; Combined Modality Therapy; Cystoscopy; Doxorubicin; Human | 1987 |
5-year experience with intravesical therapy of carcinoma in situ: an inquiry into the risks of "conservative" management.
Topics: Administration, Intravesical; Antineoplastic Combined Chemotherapy Protocols; BCG Vaccine; Carcinoma | 1987 |
Transitional cell carcinoma of the prostate following intravesical therapy for transitional cell carcinoma of the bladder.
Topics: Administration, Intravesical; Aged; Antineoplastic Agents; BCG Vaccine; Carcinoma, Transitional Cell | 1988 |
Review of Mayo Clinic experience with carcinoma in situ.
Topics: Administration, Topical; BCG Vaccine; Carcinoma in Situ; Doxorubicin; Hematoporphyrins; Humans; Hype | 1985 |